Pro Bono Advice
The EMA is offering scientists free advice on the development of therapeutics to treat COVID-19
Maryam Mahdi | | Quick Read
Developers of potential therapeutics or vaccines for COVID-19 have been invited to contact the EMA as soon as possible to take advantage of the full fee waiver the agency is offering for fast-tracked scientific advice applications. The agency will identify products mature enough to benefit from the fast-track advice service, which includes preliminary informal comments, feedback on development programs as well as guidance on best methods, study designs, and the efficacy and safety of products.
In addition to the fast-track scientific advice service, the EMA also reminds drug companies that it has several other measures that can speed up the development of pertinent medicines, including the PRIME scheme (originally launched to enhance support for the development of medicines that target an unmet medical need), accelerated assessment, and conditional marketing authorization procedures.
The EMA is also working closely with other international regulatory bodies to identify effective therapeutics with prophylactic effects.
Enjoy our FREE content!
Log in or register to gain full unlimited access to all content on the The Medicine Maker site. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.